Matt Butler, Ellen Moore, James Rucker et al.
preprint
Abstract Hallucinogen persisting perceptual disorder (HPPD) is characterised by episodes of altered perception linked to past psychoactive drug use, accompanied by distress and functional impairment. To date, clinical characterisation has been limited in scale. Using TriNetX, a global federated health research network of electronic health records, we conducted a retrospective cohort study...
Wanpeng Cui, Chen Shen, Wen-Cheng Xiong et al.
preprint
Summary Ketamine is a fast-acting, long-lasting novel antidepressant. However, underpinning intracellular mechanisms remain unclear. We conducted an unbiased screening for genes that were less expressed in the prefrontal cortex (PFC) of mice that did not display antidepression-like effects to ketamine. GO analysis implicated endoplasmic reticulum and protein folding; in particular, GRP78, a...
Yuri Mochiuzki
preprint
Numerous clinical issues exist regarding the diagnostic criteria in psychiatry. To address these issues, this paper reconstructs depression and atypical psychosis through a symptomatic framework. From depression, self-infringement psychosis is derived, emphasizing its psychotic symptoms. From atypical psychosis, bewildered-state psychosis is derived, elucidating its characteristic pathology....
Sarah K. Danböck, Yoki L. Mertens, Patricia Kulla et al.
preprint
Dissociation constitutes a transdiagnostic phenomenon not only characterizing dissociative disorders but also occurring across a broad range of psychiatric disorders like posttraumatic stress disorder, borderline personality disorder, depression, and psychosis. In the latter disorders, moderate types of dissociative symptomatology like depersonalization, derealization, or gaps in awareness...
Ling Qiu, Xuhui Chen, Fu Jia et al.
preprint
Abstract Objective Patients with Postherpetic Neuralgia (PHN) often exhibit depressive-like symptoms, significantly impacting their quality of life. Esketamine, known for its analgesic properties, has also been recognized for its rapid antidepressant effects. However, its efficacy in the treatment of PHN requires further exploration. This study aims to evaluate the impact of intravenous...
Shixia Xu, Jiaojiao Yang, Jing Li et al.
preprint
Abstract Background Postpartum depression (PPD) is a common mental disease in postpartum women, which has received more and more attention in society. Ketamine has been confirmed for its rapid antidepressant effect in women with PPD. We speculate that esketamine, an enantiomer of ketamine, pretreatment during cesarean can also reduce the incidence of PPD. Methods All the parturients enrolled in...
Brandon G. Truax
preprint
ABSTRACT Aims To investigate real-world treatment attrition, concomitant use of pharmaceuticals with known drug-interactions, total cost of care, claims-based outcomes, and health disparities for individuals initiated on esketamine therapy in the United States. Methods Individuals aged 18-64 with >=1 adjudicated claim for esketamine intranasal spray from 2019 to 2022 in the Optum Labs Data...
Sophie Holland
This paper explores ketamine as a psychedelic alongside the differential impacts of psychedelic versus psycholytic effects of ketamine in a therapeutic setting. The paper examines existing research to elucidate the broad therapeutic potential of ketamine and the mechanisms underlying each modality. The primary objective is to present the differences between psychedelic and psycholytic...
Lena K L Oestreich, Hugh McGovern, Zohaib Nadeem et al.
preprint
Background: The therapeutic use of 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin has gained interest due to their potential efficacy in treating mental illness. We systematically reviewed the efficacy of MDMA and psilocybin in treating mental illness and explored the moderating effects of dosage, psychotherapeutic support, and concurrent antidepressant use. Methods: In this systematic...
Yunong Bai, Simon N. Vandekar, Brandee Feola et al.
Abstract Objective Tobacco and cannabis are the most used substances among individuals at clinical high risk for psychosis (CHR-P), but it remains controversial whether substance use drives symptom exacerbation and psychosis transition, or vice versa. We investigated longitudinal dose-response relationships of tobacco and cannabis use with clinical presentation in a CHR-P population. Methods...